Page 1

ContextVision ContextVision : Assessing a Digital Pathology spin - off with a listing on Euronext Growth STOCKHOLM - August 26 , 2021 - ContextVision , a medical technology software company specializing in image processing and decision support tools within digital pathology , today announces that the Board of Directors of ContextVision is conducting a review of the company's structure , and has initiated work assessing a spin - off of the Digital Pathology unit with a goal of listing the new entity on the Euronext Growth on the Oslo Stock Exchange . The review is expected to be concluded by the end of the fourth quarter 2021 . ContextVision's Board of Directors believes a split of the Company - with one entity consisting of Medical Imaging , the other of Digital Pathology - could accelerate the long - term business growth and success of both entities , hence creating substantial shareholder value . " Strong differentiated investor appeal " Since the company's inception nearly 40 years ago , ContextVision has become a global market leader within image enhancement , as a trusted partner to leading manufacturers of ultrasound , X- ray and MRI equipment around the world . Since 2015 , the company is one of the pioneers within digital pathology , developing decision support tools for detecting prostate cancer using artificial intelligence and deep learning . " We believe the time is right to assess creating two separate companies . So far , we have benefited greatly from being one closely knit organization but going forward , we believe the company might prosper more as two separate entities . We have reached a stage where it is our responsibility to evaluate whether a full strategic focus on each business is more important than the synergies offered by continuing as one company , " says CEO Fredrik Palm of ContextVision . " The Board of Directors and Management have for a while seen a split as a natural evolution of the company in order to maximize potential and long - term shareholder value . By splitting ContextVision , two clean - cut investment alternatives are formed , both with exciting futures and strong differentiated investor appeal , " says chairman Olof Sandén of ContextVision . Increased demand for core products The Company's core business , Medical Imaging , has never been as strong as now , delivering annual margins of around 40 percent over the last couple of years . " We see an increasing demand for our image quality products and believe that a full focus - with no disturbance from developing new technologies - will help further develop the Medical Imaging business , where Context Vision holds a unique market leader position , " says Palm . Last year , ContextVision saw the release of the company's first digital pathology product , INIFY Prostate Screening . As it transitions into the next phase , the need to focus within the whole organization is clear . " INIFY Prostate is our market entrance product . It will be further developed for prostate as well as for additional cancer types , such as colorectal cancer . In addition , we are also considering other business opportunities that the digitalization of pathology offers . The market is maturing step by step , and has a huge potential , " says Palm .